Weilan Biotech announced that on December 26, 2025, the company held the 22nd meeting of the 5th board of directors to review and pass the 2026 daily related transaction forecast bill, and there is no need to submit it to the shareholders' meeting for review. From January to November 2025, the company actually sold products to Beidahuang Baoquanling Agriculture and Animal Husbandry Development Co., Ltd. and its subsidiaries for 8.0795 million yuan, which was lower than the estimated amount of 15 million yuan due to market conditions. In 2026, the company expects to sell products such as enzyme preparations to it for 15 million yuan, accounting for 1.23% of similar business. Deal pricing is based on market prices and does not affect the company's independence.

Weilan Biotech announced that on December 26, 2025, the company held the 22nd meeting of the 5th board of directors to review and pass the 2026 daily related transaction forecast bill, and there is no need to submit it to the shareholders' meeting for review. From January to November 2025, the company actually sold products to Beidahuang Baoquanling Agriculture and Animal Husbandry Development Co., Ltd. and its subsidiaries for 8.0795 million yuan, which was lower than the estimated amount of 15 million yuan due to market conditions. In 2026, the company expects to sell products such as enzyme preparations to it for 15 million yuan, accounting for 1.23% of similar business. Deal pricing is based on market prices and does not affect the company's independence.